<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38027" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Leflunomide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38027.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Leflunomide is a medication used in the management and treatment of rheumatoid arthritis. It is in the non-biological DMARDs class of medications. This activity reviews the indications, action, and contraindications for leflunomide as a valuable agent in treating and managing rheumatoid arthritis. This activity will highlight the mechanism of action, adverse event profile, and other key factors of leflunomide use in a clinical setting, pertinent to members of the interprofessional team in the care of patients with rheumatoid arthritis and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of leflunomide.</p></list-item><list-item><p>Describe the potential adverse effects of leflunomide.</p></list-item><list-item><p>Review the appropriate monitoring of leflunomide.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to advance leflunomide use in the care of rheumatoid arthritis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38027&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38027">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38027.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Leflunomide is a disease-modifying antirheumatic drug (DMARDs), which is FDA approved to treat individuals with rheumatoid arthritis.<xref ref-type="bibr" rid="article-38027.r1">[1]</xref><xref ref-type="bibr" rid="article-38027.r2">[2]</xref>&#x000a0;It is a non-biological novel isoxazole derivative that has demonstrated anti-inflammatory and immunomodulatory characteristics.<xref ref-type="bibr" rid="article-38027.r3">[3]</xref>&#x000a0;Leflunomide maintains function in rheumatoid arthritis by delaying articular cartilage and bone disintegration and limiting irreversible joint damage. The medication is&#x000a0;also useful in preventing synovitis and&#x000a0;managing systemic&#x000a0;symptoms&#x000a0;of the disease.<xref ref-type="bibr" rid="article-38027.r4">[4]</xref>&#x000a0;Leflunomide is also indicated for the treatment of psoriatic arthritis and would be a reliable and beneficial option for individuals with the disease.<xref ref-type="bibr" rid="article-38027.r5">[5]</xref>&#x000a0;Despite the efficacy of improving swollen and tender joints, there is no FDA approval for the treatment of psoriatic arthritis due to minimal impact on the improvement of skin psoriasis.<xref ref-type="bibr" rid="article-38027.r6">[6]</xref>&#x000a0;Being a potent dihydro-orotate dehydrogenase inhibitor, leflunomide has been clinically assessed for cancer treatment but failed to&#x000a0;secure FDA approval.<xref ref-type="bibr" rid="article-38027.r7">[7]</xref>&#x000a0;The indication for its use as a treatment of cancer comes from the inhibition of dihydro-orotate dehydrogenase, which arrests the S-phase in the cell cycle and can slow the rapid proliferation of cancer cells.<xref ref-type="bibr" rid="article-38027.r7">[7]</xref></p>
      </sec>
      <sec id="article-38027.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Leflunomide is an immunomodulatory oral medication that becomes metabolized in the body to its active form metabolite A77-1726, also known as teriflunomide. This metabolite acts by inhibiting the mitochondrial enzyme dihydro-orotate dehydrogenase.<xref ref-type="bibr" rid="article-38027.r8">[8]</xref><xref ref-type="bibr" rid="article-38027.r9">[9]</xref>&#x000a0;This action prevents the synthesis of ribonucleotide uridine monophosphate pyrimidine (rUMP) and decreases rUMP levels, further activating P53. The activation of P53 restricts the progression of&#x000a0;the G1 to S-phase in the cell cycle.<xref ref-type="bibr" rid="article-38027.r8">[8]</xref><xref ref-type="bibr" rid="article-38027.r9">[9]</xref>&#x000a0;This restriction halts the proliferation of activated and autoimmune lymphocytes promoting anti-inflammatory and immunomodulatory effects.<xref ref-type="bibr" rid="article-38027.r8">[8]</xref><xref ref-type="bibr" rid="article-38027.r9">[9]</xref><xref ref-type="bibr" rid="article-38027.r3">[3]</xref></p>
      </sec>
      <sec id="article-38027.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Leflunomide is available in oral tablets and comes in the following dosages:</p>
        <list list-type="bullet">
          <list-item>
            <p>10 mg</p>
          </list-item>
          <list-item>
            <p>20 mg</p>
          </list-item>
          <list-item>
            <p>100 mg</p>
          </list-item>
        </list>
        <p>Patients can be started on an oral loading dose of 100 mg&#x000a0;once a day for three days, followed by a maintenance dose of&#x000a0;10 mg or 20 mg per day -depending on the patient's tolerance. These are the recommended dosages for the treatment of Rheumatoid arthritis.<xref ref-type="bibr" rid="article-38027.r10">[10]</xref><xref ref-type="bibr" rid="article-38027.r11">[11]</xref>&#x000a0;Patients may start to notice the effectiveness of leflunomide after 4 to 8 weeks of treatment.<xref ref-type="bibr" rid="article-38027.r10">[10]</xref>&#x000a0;The 100 mg loading dose&#x000a0;is only for administration to select individuals due to&#x000a0;an initial increased rate of adverse events.<xref ref-type="bibr" rid="article-38027.r2">[2]</xref><xref ref-type="bibr" rid="article-38027.r12">[12]</xref></p>
      </sec>
      <sec id="article-38027.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects of leflunomide include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Elevation in liver enzymes</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Back pain</p>
          </list-item>
          <list-item>
            <p>Alopecia</p>
          </list-item>
        </list>
        <p>Less common effects are hematological disorders, such as pancytopenia, and pulmonary disorders such as interstitial lung disease and pneumonitis.<xref ref-type="bibr" rid="article-38027.r2">[2]</xref><xref ref-type="bibr" rid="article-38027.r10">[10]</xref><xref ref-type="bibr" rid="article-38027.r13">[13]</xref>&#x000a0;Hepatic injury can begin to resolve within seven days of terminating the medication.<xref ref-type="bibr" rid="article-38027.r11">[11]</xref>&#x000a0;If ALT levels soar above three times the normal limits, repeat liver function tests, and modify the medication dosage.<xref ref-type="bibr" rid="article-38027.r11">[11]</xref>&#x000a0;If levels remain elevated, the prescriber should discontinue the medication.</p>
        <p>Leflunomide can also cause reversible inhibition of MAO-A and MAO-B receptors but is only slightly effective as an MAO inhibitor. Researchers studied it for the treatment of Parkinson disease.<xref ref-type="bibr" rid="article-38027.r14">[14]</xref></p>
      </sec>
      <sec id="article-38027.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>Teratogenicity with leflunomide contraindicates its use during pregnancy and warrants discretion in females during childbearing years.<xref ref-type="bibr" rid="article-38027.r15">[15]</xref>&#x000a0;Discontinuing leflunomide due to concerns for fetal safety during a planned pregnancy is indicated.<xref ref-type="bibr" rid="article-38027.r16">[16]</xref>&#x000a0;The recommendation is that the patient stops leflunomide three months prior to pregnancy.<xref ref-type="bibr" rid="article-38027.r17">[17]</xref></p>
        <p>
<bold>Liver impairment</bold>
</p>
        <p>Leflunomide is contraindicated in severe hepatic impairment due to hepatotoxicity.</p>
        <p>
<bold>Lung Disease</bold>
</p>
        <p>Leflunomide is also contraindicated in patients with underlying Interstitial lung disease and can cause symptoms within three months of starting leflunomide.<xref ref-type="bibr" rid="article-38027.r18">[18]</xref></p>
        <p>Other contraindications include hypersensitivity, previous or current skin reactions, immunosuppression, and impaired bone marrow function.</p>
      </sec>
      <sec id="article-38027.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>Liver function tests</p>
          </list-item>
          <list-item>
            <p>CBC</p>
          </list-item>
          <list-item>
            <p>Blood pressure</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
        </list>
        <p>Leflunomide&#x000a0;black box label&#x000a0;warning&#x000a0;warrants periodic monitoring of hepatic enzymes&#x000a0;every four weeks for the initial six months and every other month after that.<xref ref-type="bibr" rid="article-38027.r11">[11]</xref><xref ref-type="bibr" rid="article-38027.r19">[19]</xref><xref ref-type="bibr" rid="article-38027.r20">[20]</xref>&#x000a0;In pregnancy, the labeled warnings&#x000a0;indicate an enhanced risk of fetal mortality or teratogenic impacts in pregnant women.<xref ref-type="bibr" rid="article-38027.r20">[20]</xref>&#x000a0;The active metabolite of leflunomide, A77 1726, has a two-week half-life,&#x000a0;a significant limitation to the medication when adverse events occur.<xref ref-type="bibr" rid="article-38027.r10">[10]</xref>&#x000a0;This factor can cause&#x000a0;the effects&#x000a0;to start or continue even after stopping leflunomide therapy. Routine monitoring is advisable when used with other hepatotoxic and hemotoxic agents.<xref ref-type="bibr" rid="article-38027.r21">[21]</xref>&#x000a0;Immunosuppression is also a black box warning of leflunomide; a CBC is necessary for all patients before and after beginning leflunomide treatment.<xref ref-type="bibr" rid="article-38027.r2">[2]</xref>&#x000a0;Hypertension is an adverse effect of leflunomide, for which blood pressure requires routine monitoring.<xref ref-type="bibr" rid="article-38027.r2">[2]</xref></p>
      </sec>
      <sec id="article-38027.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Cholestyramine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Four grams of cholestyramine every 6 hours for 14 days is the recommended intervention for wash-out therapy due to the long half-life of leflunomide.<xref ref-type="bibr" rid="article-38027.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>Leflunomide toxicity can affect the liver by causing acute drug-induced hepatic injury and affect the pulmonary system through pneumonitis and interstitial lung disease. During these complications, discontinuation of leflunomide and empirical cholestyramine wash-out therapy is recommended for toxicity.<xref ref-type="bibr" rid="article-38027.r22">[22]</xref><xref ref-type="bibr" rid="article-38027.r23">[23]</xref>&#x000a0;Leflunomide causes aryl hydrocarbon receptor signaling, which acts on pulmonary and hepatic CYP1A enzymes.<xref ref-type="bibr" rid="article-38027.r24">[24]</xref>&#x000a0;Excess aryl hydrocarbon receptor signaling leads to several pathologic states in the lung and liver.<xref ref-type="bibr" rid="article-38027.r24">[24]</xref>&#x000a0;Pancytopenia can also result due to leflunomide toxicity. The treatment goal is the same as drug-induced hepatic injury and&#x000a0;drug-induced pneumonitis, which is leflunomide-eliminating cholestyramine treatment.<xref ref-type="bibr" rid="article-38027.r13">[13]</xref></p>
      </sec>
      <sec id="article-38027.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Leflunomide is an FDA-approved medication indicated for the treatment of rheumatoid arthritis. Managing the treatment of patients prescribed leflunomide requires excellent communication between the patient and professional healthcare providers. These providers need to function as an interprofessional team to include a primary care physician, a rheumatologist, a nurse, and a pharmacist. The primary care physicians and rheumatologists necessitate excellent patient rapport, so the patient fully understands the importance of medication compliance and education on the treatment and illness. It is vital to be engaged in the patient's care, so relapses, remissions, and disability do not occur long term.</p>
        <p>The primary care and specialist should be familiar with leflunomide, its implications, and adverse effects. The patients prescribed leflunomide need routine checkups to observe if the medication is in an optimal range and the patient is not experiencing elevation in liver enzymes. Collective decision-making and interprofessional communication are necessary elements to enhance patient-centered care and achieve the desired outcome. Without the proper care and communication of an interprofessional team of healthcare professionals, the risk of adverse events and leflunomide toxicity, including drug-induced hepatitis, drug-induced pneumonitis, pancytopenia, and harm to the fetus during pregnancy, is highly likely.&#x000a0;An interprofessional healthcare team&#x000a0;working&#x000a0;across disciplinary lines providing an integrated, evidence-based strategy to patients receiving treatment with leflunomide will help deliver the best possible outcomes.<xref ref-type="bibr" rid="article-38027.r25">[25]</xref></p>
      </sec>
      <sec id="article-38027.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38027&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38027">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38027/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38027">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38027.s11">
        <title>References</title>
        <ref id="article-38027.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide Aventis Pharma.</article-title>
            <source>Curr Opin Investig Drugs</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>222</fpage>
            <page-range>222-30</page-range>
            <pub-id pub-id-type="pmid">11816835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldenberg</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.</article-title>
            <source>Clin Ther</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1837</fpage>
            <page-range>1837-52; discussion 1821</page-range>
            <pub-id pub-id-type="pmid">10890256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alldred</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-37</page-range>
            <pub-id pub-id-type="pmid">11336574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>Leflunomide for rheumatoid arthritis.</article-title>
            <source>Drug Ther Bull</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>52</fpage>
            <page-range>52-4</page-range>
            <pub-id pub-id-type="pmid">11027115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dai</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of leflunomide in psoriatic arthritis treatment: A single-arm meta-analysis.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>1498</fpage>
            <page-range>1498-1505</page-range>
            <pub-id pub-id-type="pmid">31134727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kozicky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Use of FDA-Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic.</article-title>
            <source>ACR Open Rheumatol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>1</volume>
            <issue>9</issue>
            <fpage>580</fpage>
            <page-range>580-584</page-range>
            <pub-id pub-id-type="pmid">31777842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madak</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Bankhead</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cuthbertson</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Showalter</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Neamati</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.</article-title>
            <source>Pharmacol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>195</volume>
            <fpage>111</fpage>
            <page-range>111-131</page-range>
            <pub-id pub-id-type="pmid">30347213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of leflunomide in rheumatoid arthritis.</article-title>
            <source>J Rheumatol Suppl</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>53</volume>
            <fpage>20</fpage>
            <page-range>20-6</page-range>
            <pub-id pub-id-type="pmid">9666414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Frangou</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Wahl</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kirschbaum</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action for leflunomide in rheumatoid arthritis.</article-title>
            <source>Clin Immunol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-208</page-range>
            <pub-id pub-id-type="pmid">10600330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <article-title>Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.</article-title>
            <source>Prescrire Int</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>52</issue>
            <fpage>36</fpage>
            <page-range>36-9</page-range>
            <pub-id pub-id-type="pmid">11718154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Leflunomide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31644034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolosiu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perdriset</surname>
                <given-names>G</given-names>
              </name>
              <collab>LEADER Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1132</fpage>
            <page-range>1132-40</page-range>
            <pub-id pub-id-type="pmid">23401601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toyokawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kingetsu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurosaka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient.</article-title>
            <source>Mod Rheumatol</source>
            <year>2007</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>436</fpage>
            <page-range>436-40</page-range>
            <pub-id pub-id-type="pmid">17929140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petzer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Petzer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide, a Reversible Monoamine Oxidase Inhibitor.</article-title>
            <source>Cent Nerv Syst Agents Med Chem</source>
            <year>2016</year>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>112</fpage>
            <page-range>112-9</page-range>
            <pub-id pub-id-type="pmid">26299850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.</article-title>
            <source>Open Access Rheumatol</source>
            <year>2010</year>
            <volume>2</volume>
            <fpage>53</fpage>
            <page-range>53-71</page-range>
            <pub-id pub-id-type="pmid">27789998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;testam Skorpen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoeltzenbein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tincani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer-Betz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elefant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nelson-Piercy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cetin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Costedoat-Chalumeau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dolhain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khamashta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruiz-Irastorza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vencovsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caeyers</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zumb&#x000fc;hl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>&#x000d8;stensen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>795</fpage>
            <page-range>795-810</page-range>
            <pub-id pub-id-type="pmid">26888948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schioppo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Meroni</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Challenges and treatment options for rheumatoid arthritis during pregnancy.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1539</fpage>
            <page-range>1539-47</page-range>
            <pub-id pub-id-type="pmid">27283340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raj</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nugent</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide-induced interstitial lung disease (a systematic review).</article-title>
            <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
            <year>2013</year>
            <month>Nov</month>
            <day>22</day>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-76</page-range>
            <pub-id pub-id-type="pmid">24284289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xuan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Couch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tolleson</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial dysfunction induced by leflunomide and its active metabolite.</article-title>
            <source>Toxicology</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>396-397</volume>
            <fpage>33</fpage>
            <page-range>33-45</page-range>
            <pub-id pub-id-type="pmid">29427785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Frangou</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Wahl</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kirschbaum</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>How does leflunomide modulate the immune response in rheumatoid arthritis?</article-title>
            <source>BioDrugs</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-15</page-range>
            <pub-id pub-id-type="pmid">18031184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2004</year>
            <month>May</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-309, vi</page-range>
            <pub-id pub-id-type="pmid">15172042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stine</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2016</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-36</page-range>
            <pub-id pub-id-type="pmid">26633044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>389</fpage>
            <page-range>389-92</page-range>
            <pub-id pub-id-type="pmid">19955995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paramahamsa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moorthy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shivanna</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide Induces Pulmonary and Hepatic CYP1A Enzymes via Aryl Hydrocarbon Receptor.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1966</fpage>
            <page-range>1966-70</page-range>
            <pub-id pub-id-type="pmid">26417045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38027.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijesinghe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Galappatthy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seneviratne</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Saravanamuttu</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Udagama</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelleher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Senerath</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fernandopulle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weerasekera</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Wijayaratne</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2017</year>
            <month>Jul</month>
            <day>19</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>310</fpage>
            <pub-id pub-id-type="pmid">28724365</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
